[Introduction. Diabetes type 2]

Same author

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Diabetes & metabolism·2019

Same author

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Diabetes & metabolism·2018

Same author

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Diabetes & metabolism·2017

Same author

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes.

Diabetes & metabolism·2017

Same author

Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial.

Diabetes & metabolism·2016

Same author

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.

Diabetes research and clinical practice·2016

Same journal

[Prolonged fever].

La Revue du praticien·2026

Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026

Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026

Same journal

[Patient education in heart failure].

La Revue du praticien·2026

Related Experiment Videos

[Introduction. Diabetes type 2]

Related Concept Videos

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes.

Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial.

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.

[Prolonged fever].

[Lower gastrointestinal bleeding].

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

[A history of child abuse intervention in the West].

[Agranulocytose médicamenteuse].

[Patient education in heart failure].

Related Experiment Videos

[Introduction. Diabetes type 2]

Related Concept Videos

Related Articles

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes.

Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial.

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.

[Prolonged fever].

[Lower gastrointestinal bleeding].

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

[A history of child abuse intervention in the West].

[Agranulocytose médicamenteuse].

[Patient education in heart failure].